Vivek Subbiah
ECOG-ACRIN Cancer Research Group · Stanford University · M.D. Anderson Cancer Center
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Vivek Subbiah as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 16:26 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT06400225 · Testing BVD-523FB (Ulixertinib) as Potentially Targeted Treatment in Cancers With Genetic Changes (MATCH - Subprotocol Z1L)National Cancer Institute (NCI) · active not recruiting · Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Refractory Lymphoma · principal investigator
- N/ANCT04504604 · TCF-001 TRACK (Target Rare Cancer Knowledge) StudyTargetCancer Foundation · recruiting · Rare Cancers, Cholangiocarcinoma, Cancer of Unknown Primary Site · principal investigator
- N/ANCT04028479 · The Registry of Oncology Outcomes Associated With Testing and TreatmentTaproot Health · completed · Adenocarcinoma, Adenocystic Carcinoma, Anal Cancer · principal investigator
- Ph1NCT03430882 · Sapanisertib, Carboplatin, and Paclitaxel in Treating Patients With Recurrent or Refractory Malignant Solid TumorsM.D. Anderson Cancer Center · completed · Recurrent Malignant Solid Neoplasm, Refractory Malignant Solid Neoplasm · principal investigator
- Ph1NCT03188328 · Safety, Tolerability, PK, Dosimetry, MTD and Preliminary Efficacy of Intra-lesionally Injected AvidinOX, Followed by IV Escalating Doses of [177Lu]DOTA-biotin in Pts With Injectable Solid Tumors or LymphomasAlfasigma S.p.A. · terminated · Inoperable Solid Tumors or Lymphomas · principal investigator
- Ph1NCT03017833 · Sapanisertib and Metformin in Treating Patients With Advanced or Metastatic Relapsed or Refractory CancersM.D. Anderson Cancer Center · completed · Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Recurrent Malignant Solid Neoplasm · principal investigator
- Ph1/Ph2NCT02842125 · Safety and Efficacy of Intra-Arterial and Intra-Tumoral Ad-p53 With Capecitabine (Xeloda) or Anti-PD-1 in Liver Metastases of Solid Tumors and Recurrent Head and Neck Squamous Cell CancerMultiVir, Inc. · terminated · Metastatic Solid Tumor Cancer, Recurrent Head and Neck Cancer · principal investigator
- Ph1NCT02095054 · Regorafenib and Cetuximab in Patients With Advanced MalignancyM.D. Anderson Cancer Center · completed · Advanced Cancers · principal investigator
- Ph1NCT01957735 · BP31510 (Ubidecarenone,USP) Nanosuspension for Intravenous Injection to Patients With Solid TumorsBPGbio · completed · Metastatic Cancer, Cancer, Solid Tumor · principal investigator
- Ph1/Ph2NCT01833520 · Phase I Dose Escalation of Monthly Intravenous Ra-223 Dichloride in OsteosarcomaM.D. Anderson Cancer Center · completed · Sarcoma · principal investigator
- Ph1NCT01596140 · Vemurafenib in Combination With Everolimus or Temsirolimus With Advanced CancerM.D. Anderson Cancer Center · completed · Advanced Cancer, Solid Tumor · principal investigator
- Ph2NCT00094445 · Trial of Curcumin in Advanced Pancreatic CancerM.D. Anderson Cancer Center · completed · Pancreatic Neoplasms, Adenocarcinoma · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-11 16:26 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 2 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- ECOG-ACRIN Network Group Operations CenterU10CA180820 · NCI · ECOG-ACRIN MEDICAL RESEARCH FOUNDATION · PI Peter J ODwyer, MITCHELL D. SCHNALL · fiscal years 2015 to 2026Named on NCT06400225
- Experimental Medicine ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI FUNDA MERIC-BERNSTAM · fiscal years 2015 to 2026Named on NCT03017833
- R21CA104337RePORTER returned no project for this number; it is shown as the registry gives it.Named on NCT00094445
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-11 16:26 UTC. The ranking covers the 200 most relevant of 113 PubMed records, and a shared surname and initials can bring in a namesake. All 113 on PubMed
- Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations.N Engl J Med · 20151,444 citationsRCR 41.8
- Dabrafenib and Trametinib Treatment in Patients With Locally Advanced or Metastatic BRAF V600-Mutant Anaplastic Thyroid Cancer.J Clin Oncol · 2018710 citationsRCR 25.4
- Efficacy of Selpercatinib in RET Fusion-Positive Non-Small-Cell Lung Cancer.N Engl J Med · 2020658 citationsRCR 27.4
- Efficacy of Selpercatinib in RET-Altered Thyroid Cancers.N Engl J Med · 2020647 citationsRCR 29.3
- Dabrafenib plus trametinib in patients with BRAFV600E-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial.Lancet Oncol · 2020423 citationsRCR 17.3
- Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial.Lancet Oncol · 2020401 citationsRCR 16.2
- 396 citationsRCR 26.3
- Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study.Lancet Oncol · 2021365 citationsRCR 19.2
- 359 citationsRCR 11.3
- Complex I inhibitor of oxidative phosphorylation in advanced solid tumors and acute myeloid leukemia: phase I trials.Nat Med · 2023357 citationsRCR 30.6